Grant: Project Grant
McMaster University
$100,000.00
Randomized Phase II Trial of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer
EF 2016-17
Résumé
Breast cancer that metastasizes following initial primary therapy is generally managed with systemic therapy, including hormonal therapy, chemotherapy, biologics, and bone protecting agents (bisphosphonates). A proportion of patients with metastatic breast cancer may present with disease that is limited to 5 or less separate areas, called oligometastases. Patients with oligometastases may generally do better than those with more widespread disease, but most progress after systemic therapy. Systemic therapy may not work as well in that it is less effective in treating visible disease, so by controlling each site of oligometastatic breast cancer with an aggressive local treatment, this will allow systemic therapy to work better, will prevent further distant cancer spread, and may prolong survival.
We plan to study the use of stereotactic body radiotherapy (SBRT) in patients who present with oligometastatic breast cancer. SBRT refers to highly potent doses of radiation delivered in a short time frame (less than or equal to 5-6 treatments). SBRT is a non-invasive therapy that has been shown to be safe, effective, and relatively non-toxic for multiple body sites. The objective of our study is to determine if SBRT in addition to standard systemic therapy improves the time before distant breast cancer spread, as compared to systemic therapy alone. Positive results from this trial will lead to larger trials that will hopefully establish SBRT as an effective treatment option in these patients.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
366611
Name
Swaminath Anand
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Project Grant Competition
Projecttitle
Randomized Phase II Trial of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Breast Cancer; Oligometastases; Radiation Therapy; Stereotactic Radiation
Abstract
Breast cancer that metastasizes following initial primary therapy is generally managed with systemic therapy, including hormonal therapy, chemotherapy, biologics, and bone protecting agents (bisphosphonates). A proportion of patients with metastatic breast cancer may present with disease that is limited to 5 or less separate areas, called oligometastases. Patients with oligometastases may generally do better than those with more widespread disease, but most progress after systemic therapy. Systemic therapy may not work as well in that it is less effective in treating visible disease, so by controlling each site of oligometastatic breast cancer with an aggressive local treatment, this will allow systemic therapy to work better, will prevent further distant cancer spread, and may prolong survival.
We plan to study the use of stereotactic body radiotherapy (SBRT) in patients who present with oligometastatic breast cancer. SBRT refers to highly potent doses of radiation delivered in a short time frame (less than or equal to 5-6 treatments). SBRT is a non-invasive therapy that has been shown to be safe, effective, and relatively non-toxic for multiple body sites. The objective of our study is to determine if SBRT in addition to standard systemic therapy improves the time before distant breast cancer spread, as compared to systemic therapy alone. Positive results from this trial will lead to larger trials that will hopefully establish SBRT as an effective treatment option in these patients.
Competitiondate
201611
Approvedterm2
1 yr 0 mth
Pinamesdelim
Swaminath, Anand
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~